Project Details
Description
A Phase 2, Randomized Study to Assess the Safety and Anti-Cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections that are Resistant or Refractory to Treatment with Ganciclovir/Valganciclovir or Foscarnet in Transpl
| Status | Finished |
|---|---|
| Effective start/end date | 8/1/12 → 7/31/15 |
Funding
- VIROPHARMA INCORPORATED
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.